Effect of methylphenidate treatment during adolescence on norepinephrine transporter function in orbitofrontal cortex in a rat model of attention deficit hyperactivity disorder
dc.contributor.author | Somkuwar, Sucharita S. | en_US |
dc.contributor.author | Kantak, Kathleen M. | en_US |
dc.contributor.author | Dwoskin, Linda P. | en_US |
dc.coverage.spatial | Netherlands | en_US |
dc.date | 2015-02-03 | |
dc.date.accessioned | 2017-11-20T19:28:37Z | |
dc.date.available | 2017-11-20T19:28:37Z | |
dc.date.issued | 2015-08-30 | |
dc.identifier | https://www.ncbi.nlm.nih.gov/pubmed/25680322 | |
dc.identifier.citation | Sucharita S. Somkuwar, Kathleen M. Kantak, Linda P. Dwoskin. 2015. "Effect of methylphenidate treatment during adolescence on norepinephrine transporter function in orbitofrontal cortex in a rat model of attention deficit hyperactivity disorder.." J Neurosci Methods, v. 252, pp. 55 - 63. | |
dc.identifier.issn | 1872-678X | |
dc.identifier.uri | https://hdl.handle.net/2144/25616 | |
dc.description.abstract | Attention deficit hyperactivity disorder (ADHD) is associated with hypofunctional medial prefrontal cortex (mPFC) and orbitofrontal cortex (OFC). Methylphenidate (MPH) remediates ADHD, in part, by inhibiting the norepinephrine transporter (NET). MPH also reduces ADHD-like symptoms in spontaneously hypertensive rats (SHRs), a model of ADHD. However, effects of chronic MPH treatment on NET function in mPFC and OFC in SHR have not been reported. In the current study, long-term effects of repeated treatment with a therapeutically relevant oral dose of MPH during adolescence on NET function in subregions of mPFC (cingulate gyrus, prelimbic cortex and infralimbic cortex) and in the OFC of adult SHR, Wistar-Kyoto (WKY, inbred control) and Wistar (WIS, outbred control) rats were determined using in vivo voltammetry. Following local ejection of norepinephrine (NE), uptake rate was determined as peak amplitude (Amax)× first-order rate constant (k-1). In mPFC subregions, no strain or treatment effects were found in NE uptake rate. In OFC, NE uptake rate in vehicle-treated adult SHR was greater than in adult WKY and WIS administered vehicle. MPH treatment during adolescence normalized NE uptake rate in OFC in SHR. Thus, the current study implicates increased NET function in OFC as an underlying mechanism for reduced noradrenergic transmission in OFC, and consequently, the behavioral deficits associated with ADHD. MPH treatment during adolescence normalized NET function in OFC in adulthood, suggesting that the therapeutic action of MPH persists long after treatment cessation and may contribute to lasting reductions in deficits associated with ADHD. | en_US |
dc.description.sponsorship | UL1 TR000117 - NCATS NIH HHS; R01 DA011716 - NIDA NIH HHS; P50 DA005312 - NIDA NIH HHS; P50 DA05312 - NIDA NIH HHS; R01 DA11716 - NIDA NIH HHS | en_US |
dc.format.extent | p. 55-63 | en_US |
dc.language | eng | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.relation.ispartof | J Neurosci Methods | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Norepinephrine transporter | en_US |
dc.subject | In vivo voltammetry | en_US |
dc.subject | Spontaneously hypertensive rat | en_US |
dc.subject | Attention deficit/hyperactivity disorder | en_US |
dc.subject | Orbitofrontal cortex | en_US |
dc.subject | In vivo voltammetry | en_US |
dc.subject | Norepinephrine transporter | en_US |
dc.subject | Animals | en_US |
dc.subject | Electrochemistry | en_US |
dc.subject | Methylphenidate | en_US |
dc.subject | Norepinephrine | en_US |
dc.subject | Piperazines | en_US |
dc.subject | Rats, Sprague-Dawley | en_US |
dc.subject | Electrochemistry | en_US |
dc.subject | Female | en_US |
dc.subject | Male | en_US |
dc.subject | Norepinephrine plasma membrane transport proteins | en_US |
dc.subject | Norepinephrine transporter | en_US |
dc.subject | In vivo voltammetry | en_US |
dc.subject | Spontaneously hypertensive rat | en_US |
dc.subject | Attention deficit/hyperactivity disorder | en_US |
dc.subject | Orbitofrontal cortex | en_US |
dc.subject | Science & technology | en_US |
dc.subject | Life sciences & biomedicine | en_US |
dc.subject | Biochemical research methods | en_US |
dc.subject | Biochemistry & molecular biology | en_US |
dc.subject | Neurosciences & neurology | en_US |
dc.subject | Spontaneously hypertensive-rat | en_US |
dc.subject | Wistar-Kyoto rat | en_US |
dc.subject | Medial prefrontal cortex | en_US |
dc.subject | Impulsive behavior scale | en_US |
dc.subject | Deficit/hyperactivity disorder | en_US |
dc.subject | Nucleus-accumbens | en_US |
dc.subject | Dopamine uptake | en_US |
dc.subject | Animal-model | en_US |
dc.subject | Cortical alpha(2)-adrenoceptors | en_US |
dc.subject | Age factors | en_US |
dc.subject | Attention deficit disorder with hyperactivity | en_US |
dc.subject | Analysis of variance | en_US |
dc.subject | Conditioning, classical | en_US |
dc.subject | Disease models, animal | en_US |
dc.subject | Rats, inbred SHR | en_US |
dc.subject | Rats, inbred WKY | en_US |
dc.subject | Rats, Wistar | en_US |
dc.title | Effect of methylphenidate treatment during adolescence on norepinephrine transporter function in orbitofrontal cortex in a rat model of attention deficit hyperactivity disorder | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1016/j.jneumeth.2015.02.002 | |
pubs.elements-source | pubmed | en_US |
pubs.notes | Embargo: Not known | en_US |
pubs.organisational-group | Boston University | en_US |
pubs.organisational-group | Boston University, College of Arts & Sciences | en_US |
pubs.organisational-group | Boston University, College of Arts & Sciences, Department of Psychological & Brain Sciences | en_US |
pubs.publication-status | Published | en_US |
dc.identifier.orcid | 0000-0003-1866-9485 (Kantak, Kathleen M) |
This item appears in the following Collection(s)